KURA ONCOLOGY, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
KURA ONCOLOGY, INC. (KURA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $6.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-05
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $6.39M, a 86.54% increase from fiscal 2024.
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $3.42M, a 18.10% decline from fiscal 2023.
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $4.18M, a 4.60% increase from fiscal 2022.
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $4.00M, a 41.82% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 4 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $6.39M 10-K · filed 2026-03-05 | ||
| 2024-12-31 | $3.42M 10-K · filed 2026-03-05 | ||
| 2023-12-31 | $4.18M 10-K · filed 2026-03-05 | $4.13M 10-K · filed 2024-02-27 | |
| 2022-12-31 | $4.00M 10-K · filed 2025-02-28 | ||
| 2021-12-31 | $2.82M 10-K · filed 2024-02-27 | ||
| 2020-12-31 | -$304.00K 10-K · filed 2023-02-23 | ||
| 2019-12-31 | $708.00K 10-K · filed 2022-02-24 | ||
| 2018-12-31 | $870.00K 10-K · filed 2021-02-24 | ||
| 2017-12-31 | $1.05M 10-K · filed 2020-02-25 | ||
| 2016-12-31 | $564.00K 10-K · filed 2018-03-12 | ||
| 2015-12-31 | $712.00K 10-K · filed 2017-03-14 | ||
| 2014-12-31 | $80.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |